Karyopharm Therapeutics reported $5M in Interest Expense on Debt for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbott ABT:US $ 123M 12M
Amgen AMGN:US $ 281M 4M
Biocryst Pharmaceuticals BCRX:US $ 13.5M 0.59M
Bristol Myers Squibb BMY:US $ 330M 23M
Eli Lilly And LLY:US $ 86.9M 0.9M
Epizyme EPZM:US $ 497K 27K
Karyopharm Therapeutics KPTI:US $ 5M 94K
Nektar Therapeutics NKTR:US $ 13.09M 0.21M
Novartis NOVN:VX 201M 1000K
Novartis NVS:US $ 201M 1M
Pfizer PFE:US $ 316M 20M
Regeneron Pharmaceuticals REGN:US $ 14.4M 0.2M
Tg Therapeutics TGTX:US $ 1.62M 0.28M
YTE INCY:US $ 0.36M 0M